Clene (NASDAQ:CLNN) Major Shareholder Sells $34,827.95 in Stock

Posted by Ethan Ryder on May 5th, 2026

Clene Inc. (NASDAQ:CLNN – Get Free Report) major shareholder Chidozie Ugwumba sold 5,795 shares of the stock in a transaction on Friday, May 1st. The stock was sold at an average price of $6.01, for a total value of $34,827.95. Following the completion of the transaction, the insider owned 271,774 shares of the company’s stock, valued at $1,633,361.74. The trade was a 2.09% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

On Monday, May 4th, Chidozie Ugwumba sold 72,884 shares of Clene stock. The stock was sold at an average price of $6.80, for a total value of $495,611.20.
On Thursday, April 30th, Chidozie Ugwumba sold 5,736 shares of Clene stock. The stock was sold at an average price of $6.08, for a total value of $34,874.88.
On Wednesday, April 29th, Chidozie Ugwumba sold 12,170 shares of Clene stock. The stock was sold at an average price of $5.63, for a total value of $68,517.10.
On Tuesday, April 28th, Chidozie Ugwumba sold 1,591 shares of Clene stock. The stock was sold at an average price of $5.90, for a total value of $9,386.90.
On Tuesday, April 21st, Chidozie Ugwumba sold 61,345 shares of Clene stock. The stock was sold at an average price of $6.14, for a total value of $376,658.30.
On Monday, April 20th, Chidozie Ugwumba sold 4,318 shares of Clene stock. The stock was sold at an average price of $6.12, for a total value of $26,426.16.
On Friday, April 17th, Chidozie Ugwumba sold 25,040 shares of Clene stock. The stock was sold at an average price of $6.43, for a total value of $161,007.20.
On Thursday, April 16th, Chidozie Ugwumba sold 7,748 shares of Clene stock. The stock was sold at an average price of $6.40, for a total value of $49,587.20.
On Wednesday, April 15th, Chidozie Ugwumba sold 6,374 shares of Clene stock. The stock was sold at an average price of $6.48, for a total value of $41,303.52.
On Thursday, April 2nd, Chidozie Ugwumba sold 24,925 shares of Clene stock. The stock was sold at an average price of $4.81, for a total value of $119,889.25.

Clene Stock Performance

NASDAQ:CLNN traded down $1.51 during trading hours on Tuesday, hitting $6.58. The company’s stock had a trading volume of 1,272,452 shares, compared to its average volume of 363,617. The business’s 50-day moving average is $5.68 and its two-hundred day moving average is $6.47. The company has a market capitalization of $77.51 million, a PE ratio of -2.53 and a beta of 0.89. Clene Inc. has a 52-week low of $2.28 and a 52-week high of $13.50.

Clene (NASDAQ:CLNN – Get Free Report) last released its quarterly earnings data on Thursday, March 12th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.14). The business had revenue of $0.08 million during the quarter, compared to analysts’ expectations of $0.03 million. As a group, analysts predict that Clene Inc. will post -1.99 EPS for the current fiscal year.

Key Headlines Impacting Clene

Here are the key news stories impacting Clene this week:

Positive Sentiment: FDA engagement supports accelerated approval pathway for CNM?Au8, improving the drug’s regulatory outlook and potentially shortening time to market; company expects to file an NDA in Q3 2026. After Successful FDA Meeting — Clene Filing Accelerated Approval NDA for ALS
Positive Sentiment: Wall Street coverage remains constructive — recent buy ratings and price targets were reaffirmed (HC Wainwright and D. Boral Capital), supporting upside expectations if clinical/regulatory progress continues. Benzinga coverage
Neutral Sentiment: Management will present at investor conferences in early May, which may provide additional updates/clarity but are unlikely on their own to drive a material re?rating. Clene to Present at Upcoming May Conferences
Negative Sentiment: Clene priced a registered direct offering of 1,000,000 shares at $7.00 to raise roughly $7M to fund NDA preparation, trials and R&D. While proceeds reduce short?term cash risk and fund key milestones, the transaction increases share count and is a dilution catalyst that often pressures the stock. Clene Announces $7 Million Underwritten Offering of Common Stock
Negative Sentiment: Major shareholder Chidozie Ugwumba disclosed recent open?market sales (large blocks on May 1 and May 4), materially reducing his reported stake — insider selling at current levels can signal liquidity needs or trigger investor concern about near?term outlook. SEC filing: SEC Insider Trading Filing

Analysts Set New Price Targets

Several research firms have weighed in on CLNN. HC Wainwright reissued a “buy” rating and issued a $31.00 target price on shares of Clene in a report on Monday. Canaccord Genuity Group reissued a “buy” rating and issued a $48.00 target price on shares of Clene in a report on Friday, March 13th. Weiss Ratings lowered Clene from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, April 22nd. Finally, D. Boral Capital reissued a “buy” rating and issued a $23.00 target price on shares of Clene in a report on Monday. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $33.25.

Read Our Latest Analysis on Clene

Institutional Trading of Clene

Several large investors have recently bought and sold shares of the company. SymBiosis Capital Partners LLC acquired a new stake in shares of Clene during the fourth quarter valued at $4,523,000. Scoggin Management LP boosted its stake in shares of Clene by 75.1% during the third quarter. Scoggin Management LP now owns 250,000 shares of the company’s stock valued at $1,506,000 after acquiring an additional 107,250 shares during the last quarter. Ensign Peak Advisors Inc boosted its stake in shares of Clene by 668.6% during the fourth quarter. Ensign Peak Advisors Inc now owns 114,361 shares of the company’s stock valued at $671,000 after acquiring an additional 99,481 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Clene by 8.0% during the fourth quarter. Geode Capital Management LLC now owns 82,079 shares of the company’s stock valued at $482,000 after acquiring an additional 6,090 shares during the last quarter. Finally, PEAK6 LLC acquired a new stake in shares of Clene during the fourth quarter valued at $294,000. Institutional investors and hedge funds own 23.28% of the company’s stock.

Clene Company Profile

(Get Free Report)

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).